How Health Tech and Life Sciences Stories Get Into Fierce Healthcare, STAT, Endpoints and HIStalk

When to use this playbook

Your company is preparing a funding, product, regulatory, clinical, partnership, customer, research, or market-data announcement.
Leadership wants coverage in a named healthcare or life sciences outlet, but the milestone has not yet been tested against that outlet’s actual beat.
Your marketing team needs to decide whether to pitch now, strengthen the evidence, hold the story, or target a more relevant specialist publication.
You want media and analyst outreach to reinforce the same market narrative without sending the same pitch to both audiences.

What success looks like

Success is not getting the same announcement into the largest possible number of publications. It is earning credible attention from the outlets, analysts, and newsletters that influence the company’s buyers, investors, partners, and category experts.

A strong launch plan produces a short, defensible target list, an evidence package that can withstand questions, prepared executive access, and realistic expectations about which formats are attainable. No agency can guarantee editorial placement because editors retain control over what they cover.

Step 1: Define tier one around influence, not circulation

Action: Name the audience the company needs to influence, the decision that audience is making, and the sources it trusts. Rank publications according to buyer and analyst relevance, not general traffic or brand familiarity.

For a health IT company selling to health systems, HIStalk, Fierce Healthcare, MedCity News, and a relevant analyst firm can be tier one. For a genomics company, GenomeWeb may be more consequential than a larger general healthcare publication. SVM secured GenomeWeb coverage for Baylor Genetics around rare disease testing and conference research, while an early Q-VANT Biosciences launch earned a profile in Drug Discovery & Development. Both illustrate why specialist relevance can matter more than raw reach. (SVM Baylor Genetics coverage; SVM Q-VANT coverage)

Expected outcome: A tier-one list that reflects who influences the next commercial decision, followed by secondary outlets that add reach, search visibility, or regional context.

Gotchas: Do not label every national healthcare outlet tier one. An outlet becomes tier one when its audience, editorial beat, and authority match the company’s market.

Planning estimate: 45 to 60 minutes with communications, commercial, and executive stakeholders.

Step 2: Match the milestone to the outlet

Action: Compare the announcement with each outlet’s coverage mandate. The table below is a targeting framework, not a promise of acceptance. Qualification and decline triggers reflect editorial-fit judgment applied to the outlets’ published coverage areas.

Campaign examples draw from SVM’s published Pear Suite funding campaign, Upfront Healthcare program, and PathAI coverage work.
Outlet	What it covers	What makes a story qualify	What commonly weakens the pitch	Published SVM campaign example
Fierce Healthcare	Healthcare business and policy, including payers, providers, health IT, finance, operations, and industry change.	A material funding round, customer result, market dataset, policy consequence, or product development that changes how healthcare organizations operate or compete.	An incremental feature announcement, unsupported claims, or news with no clear effect on providers, payers, patients, or industry economics.	Pear Suite Series A funding; Upfront Healthcare Medicaid engagement thought leadership.
STAT	Health tech, medicine, life sciences, hospitals, insurance, public health, and the business of making medicines.	New evidence, a significant financing or deal, credible health impact, a strong accountability angle, or an exclusive development with broader industry consequences.	A routine company update, unvalidated clinical language, or a funding pitch that provides numbers but no reason the company or market matters.	Pear Suite Series A in the STAT Health Tech newsletter.
Endpoints News	Biotech and pharma science, financing, deals, regulation, leadership, R&D, and selected health technology developments.	A consequential financing, trial or regulatory milestone, biopharma partnership, leadership change, scientific readout, or health technology development with life sciences implications.	General health IT news without a biotech, pharma, scientific, financing, or market-power dimension.	Pear Suite Series A in the Health Tech Roundup.
MedCity News	B2B healthcare innovation, startups, established companies, deals, health IT, diagnostics, devices, biopharma, payer change, and provider transformation.	Funding, a strategic partnership, a meaningful deployment, a measurable operating result, or an innovation tied to a recognizable healthcare problem.	A product description without adoption, buyer consequences, market context, or a credible outside participant.	PathAI digital pathology coverage work.
HIStalk	Health IT company, product, customer, investment, acquisition, executive, and provider technology news.	A concise factual development with named customers or partners, exact transaction details, concrete health IT relevance, and information that can be summarized cleanly.	Long promotional copy, vague AI terminology, missing transaction details, or a story with no connection to health system operations.	Pear Suite Series A in Morning Headlines; Upfront Healthcare thought leadership.
Chilmark Research	Healthcare IT markets, adoption patterns, care delivery technology, engagement, analytics, interoperability, and value-based care.	Primary data, a documented customer case, informed executive access, product and market detail, or a development that helps an analyst understand category direction.	A press release presented as an analyst briefing, little primary evidence, or an executive who cannot discuss the market beyond the company’s product.	Upfront Healthcare Medicaid engagement thought leadership.
Axios Pro Deals	Health technology venture capital, private equity, mergers, acquisitions, and other material transactions.	Verified deal terms, named investors or counterparties, timing, use of funds, and a clear reason the transaction matters to the market.	No transaction, incomplete financial details, unavailable principals, or an attempt to turn a routine launch into deals news.	Pear Suite Series A in Pro Rata Premium: First Look.
Rock Health	Digital health financing, adoption, policy, consumer behavior, category trends, and healthcare technology developments.	A digital health milestone that also signals something about funding, adoption, access, care delivery, policy, or category direction.	A routine product release, a company outside digital health, or an announcement without a broader trend or ecosystem connection.	Pear Suite Series A in Rock Weekly.
BioSpace	Biotech, pharma, life sciences research, clinical development, regulation, financing, partnerships, corporate activity, and workforce news.	A scientific, clinical, regulatory, financing, partnership, manufacturing, or corporate milestone relevant to the life sciences community.	General healthcare technology with no biopharma or scientific connection, inflated scientific claims, or missing development-stage context.	PathAI life sciences announcement work. A published company announcement should be scored differently from an independently reported feature.

Expected outcome: A primary list of three to five realistic targets, plus secondary outlets selected for a distinct audience or format.

Gotchas: Do not send an identical pitch to all nine outlets. Fierce Healthcare needs a healthcare-business consequence, STAT needs a larger health or scientific reason to care, Endpoints needs a life sciences or deal dimension, and HIStalk rewards concise health IT specifics.

Planning estimate: 60 to 90 minutes for an initial outlet map.

Step 3: Build the evidence package before writing the pitch

Action: Assemble the facts an editor, reporter, or analyst will need to test the story. SVM’s media relations work includes story development, announcements, briefing materials, executive preparation, customer storytelling, and media and analyst outreach. (SVM public relations services)

For a funding announcement

Exact amount, round, close date, lead investor, participating investors, and total funding where approved.
Specific use of proceeds, not a generic promise to accelerate growth.
Evidence that explains why the company earned investment now, such as contracts, market expansion, adoption, or a defensible product capability.
Availability of the founder and an investor for questions.

For a product, clinical, or regulatory milestone

The precise product status, jurisdiction, intended use, study stage, or regulatory milestone.
The problem addressed, current alternative, and material change for the user.
Data methodology, limitations, and supporting experts.
A customer, clinical collaborator, research partner, or independent source when approved and relevant.

For a thought leadership or data story

A timely market tension that exists independently of the company.
Original data, an instructive customer case, or executive experience that adds something new.
A clear point of view with practical implications.
An executive who can discuss the category without turning every answer into a product pitch.

Expected outcome: A fact sheet, approved claims, spokesperson list, supporting data, and answers to the five hardest questions the announcement is likely to prompt.

Gotchas: “AI-powered,” “transformative,” and “first-of-its-kind” are not evidence. Any consequential superlative needs a defined comparison and support.

Planning estimate: Two to five business days, depending on data, investor, customer, legal, and regulatory approvals.

Step 4: Choose the timing, access, and format

Action: Decide whether the story supports an embargo, an exclusive, targeted advance outreach, or day-of pitching. Match the format to the strength of the news and the access available.

SVM pitched Pear Suite’s $7.6 million Series A under embargo ahead of HLTH, then conducted day-of outreach. The campaign produced coverage and newsletter mentions across STAT, Axios Pro Deals, Rock Health, Fierce Healthcare, Endpoints News, HIStalk, and other outlets. (SVM Pear Suite funding coverage)

Use an embargo when the news is material, facts are final, spokespeople are available, and reporters benefit from preparation time. Ask the outlet to agree to the embargo.
Offer an exclusive only when one outlet is the clear priority and the company accepts that other outreach will wait.
Use targeted advance outreach when the outlet may want an interview but the news is unlikely to justify an exclusive.
Use day-of outreach for concise roundup, newsletter, transaction, and headline formats, supported by fast executive availability.

Expected outcome: A launch calendar that gives high-priority outlets enough time while preserving accurate, coordinated disclosure.

Gotchas: Do not impose an embargo without agreement, offer the same exclusive to multiple outlets, or begin outreach while figures and claims are still changing.

Planning estimate: Begin focused funding outreach three to seven business days before announcement. Start conference-related planning two to four weeks ahead when interviews and executive schedules are involved.

Step 5: Run the former-journalist pitch gate

Action: Review the story as an editor would before anyone contacts the press. Former journalists add the most value when they stop weak pitches, not merely when they improve the wording.

Is it new? Identify the fact that did not exist before.
Is it consequential? Explain who is affected and what changes.
Is it provable? Attach data, transaction details, research, customer evidence, or an informed outside participant.
Is it right for this outlet? Connect the story to the publication’s actual beat and audience.
Can the executive answer difficult questions? Prepare for limitations, competitors, evidence quality, regulation, and commercial adoption.
Can the pitch be explained in two sentences? If not, the story may still lack a clear editorial angle.

SVM’s former journalists apply an editorial perspective to relevance, credibility, interviewing, and technical storytelling, while senior practitioners lead the strategy and execution. (SVM technical storytelling playbook)

Expected outcome: A smaller set of pitches with a clear reason for each recipient to care, plus an explicit hold list for stories that need more evidence or a different format.

Gotchas: Internal excitement is not external relevance. Hold the pitch when the only angle is that the company launched something, hired someone, or added a feature.

Planning estimate: 30 to 45 minutes for editorial review after the evidence package is complete.

Step 6: Coordinate analyst relations and media relations

Action: Use one evidence core, then build separate conversations for journalists and analysts.

Media relations: Lead with what is new, why it matters now, independent relevance, credible proof, and access to a useful source.
Analyst relations: Provide deeper category context, product detail, customer patterns, roadmap boundaries, competitive distinctions, and evidence that helps the analyst understand market direction.
Reinforcement: Media coverage creates public third-party evidence. Analyst conversations test whether the category argument and differentiation remain credible under deeper scrutiny.

For Upfront Healthcare, SVM combined company data, an executive viewpoint, and a customer case to engage both press and analysts. The program produced coverage in Fierce Healthcare and HIStalk, along with attention from Chilmark Research. (SVM Upfront Healthcare thought leadership)

Expected outcome: Media and analyst conversations that reinforce the same positioning while respecting the different information needs of each audience.

Gotchas: An analyst briefing is not a press pitch, and a briefing does not guarantee mention in research. Do not ask analysts to cover an announcement before giving them enough market and product context to evaluate it.

Planning estimate: One 45-minute internal alignment session, followed by separate preparation for each media interview or analyst briefing.

Step 7: Set a realistic first-year goal and score quality

Action: Set goals according to the number and strength of real milestones, then score results by influence and substance rather than counting every mention equally.

For a B2B healthcare or life sciences company with one or two genuine milestones, a realistic first-year planning benchmark is one high-fit anchor result for each strong milestone, plus two to four executive quote, contributed content, podcast, or analyst opportunities across the year. This is a planning benchmark, not a placement promise.

SVM Coverage Quality Score for evaluating earned results.
Criterion	Points	What earns the score
Audience relevance	0 to 3	The outlet reaches the buyers, analysts, investors, clinicians, or partners the program needs to influence.
Editorial depth	0 to 3	A reported feature or interview scores higher than a roundup mention or republished announcement.
Evidence carried through	0 to 2	The coverage includes the data, customer proof, transaction detail, or technical distinction that makes the story credible.
Message accuracy	0 to 2	The company, product, category, and executive viewpoint are represented accurately.
Commercial usefulness	0 to 2	The result can support buyer education, investor conversations, sales follow-up, search visibility, or executive authority.

10 to 12 points: Anchor result worth building further communications around.
7 to 9 points: Strong coverage with clear audience or commercial value.
4 to 6 points: Useful supporting visibility, but not a substitute for a high-fit anchor result.
0 to 3 points: Low-value volume that should not dominate reporting.

Expected outcome: A program that rewards influence, evidence, and buyer relevance instead of producing inflated placement counts.

Gotchas: Do not compare a full reported feature, a newsletter mention, a contributed article, and a syndicated announcement as if they were equivalent.

Planning estimate: 60 minutes for monthly review and 90 minutes for a quarterly quality and strategy review.

Frequently asked questions

How do healthcare companies get covered in Fierce Healthcare?

Healthcare companies improve their chances with Fierce Healthcare by connecting a real milestone to a provider, payer, policy, technology, workforce, or financial consequence. The pitch should explain what changed, who is affected, why the development matters now, and what evidence supports it. Customer results, market data, transaction details, and informed executive access are generally stronger than a product description alone. Fierce Healthcare focuses on healthcare news at the intersection of business and policy. (Fierce Healthcare overview)

How do you get a health tech story into STAT or Endpoints News?

A health tech story needs a larger scientific, healthcare, financing, or market consequence to fit STAT or Endpoints News. STAT covers health tech alongside medicine, hospitals, insurance, and life sciences, while Endpoints concentrates more heavily on biotech, pharma, R&D, regulation, deals, and the forces shaping those markets. A routine product release rarely clears that bar. New evidence, a consequential financing, a clinical or regulatory development, or an exclusive market change provides a more credible opening. (STAT coverage areas; Endpoints News)

What counts as a tier-one publication for a B2B healthcare company?

A tier-one publication is one that influences the company’s actual buyers, analysts, partners, investors, or category experts. It is not automatically the outlet with the largest circulation. GenomeWeb was a tier-one fit for Baylor Genetics because the story involved advanced rare disease diagnostics and sequencing. Drug Discovery & Development was highly relevant to Q-VANT Biosciences at launch because it reached the company’s specialist market. The strongest target is the source a prospective buyer would trust while evaluating the category.

How do you get an executive quoted in healthcare trade press?

An executive gets quoted by becoming useful on a live industry question, not by asking for a profile. Define two or three subjects where the executive has direct experience, a differentiated viewpoint, and evidence or examples. Prepare concise commentary that acknowledges tradeoffs and avoids product promotion. Responsiveness also matters because quote opportunities can close quickly. An ongoing program can combine media relationship building, contributed content, LinkedIn, speaking, podcasts, awards, and other executive visibility work. (SVM executive visibility services)

How should media relations and analyst relations work together for a health tech company?

Media relations and analyst relations should use the same facts and positioning but different conversations. Journalists need a timely story with public relevance, while analysts generally need deeper market, product, customer, and competitive context. Analyst discussions can test whether the category argument holds up. Media coverage can then create public evidence that buyers, analysts, search engines, and sales teams can reference. SVM used data, an executive, and a customer case to engage both press and analysts for Upfront Healthcare.

Does it matter if a PR agency has former journalists on staff?

Former journalists matter when they influence what gets pitched, what gets challenged, and what gets held back. Their main contribution is editorial judgment: identifying whether the story is genuinely new, consequential, provable, and appropriate for the target outlet. They can also prepare executives for skeptical questions and remove promotional language that weakens credibility. The benefit is not guaranteed coverage. It is fewer low-value pitches and stronger protection of the company’s reputation and media relationships.